We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Download Mobile App




Enzymatic Assay Developed for Ether Phospholipids in Plasma

By LabMedica International staff writers
Posted on 05 Mar 2018
Ethanolamine ether phospholipid (ePE) and choline ether phospholipid (ePC) are found in human plasma (serum), but the relative concentration of the ether phospholipids in the phospholipids of human serum are very low as compared to those in tissues such as leukocytes and erythrocytes.

Functions or physiological roles of the ether phospholipids in serum (plasma) are not well elucidated; however, decreases in plasmalogens in serum (plasma) have been reported in several diseases such as Alzheimer's disease, Parkinson's disease, metabolic syndrome, schizophrenia, and uremic patients.

Scientists at the Institute of Rheological Functions of Food, (Fukuoka, Japan) obtained blood samples from 12 volunteers who were aged over 70 years (76.3 ± 5.7). More...
Plasma was separated by using a clinical centrifuge at 1000g for 5 minutes. Hemolysis was checked visually and all of the plasma with hemolysis was discarded. Lipids were extracted from the plasma after treatment with Phospholipase A1.

Phospholipase A1 (PLA1) hydrolyzes diacyl phospholipids in plasma (serum) and leaves ePE and ePC intact. After lipid extraction, ePE is hydrolyzed by glycerophospholipid specific phospholipase D (GPL-PLD) to ethanolamine, and ePC is hydrolyzed by GPL-PLD to choline. Oxidation of ethanolamine is catalyzed by amine oxidase, and oxidation of choline is catalyzed by choline oxidase. The last steps are catalyzed by peroxidase, and Amplex Red reacts with hydrogen peroxide (H2O2) to produce fluorescent resorufin. The fluorescence intensity was measured using a fluorescence microplate reader. The excitation and emission wavelengths were set to 535 and 595 nm, respectively.

The team found that the amount of ePE in human plasma measured by the enzymatic method was well correlated to that by liquid chromatography-electrospray ionization-tandem mass spectrometry (LC/ESI-MS) method, but the correlation of ePC between the two methods was slightly less good than that of ePE. The authors concluded that the method is sensitive and high-throughput for assay of plasma ether phospholipids. The method may also be performed by using a colorimetric microplate readers and/or spectrophotometers. Therefore, the enzymatic method may be performed at many ordinary clinical laboratories without use of expensive apparatus. Furthermore, the enzymatic method may be applied to assay of ether phospholipids (ePE and ePC) not only in human plasma but also to assay of ePE and ePC in the other tissues. The study was published in the March 2018 issue of the journal Practical Laboratory Medicine.

Related Links:
Institute of Rheological Functions of Food


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Automated Clinical Chemistry Analyzer
Envoy 500+
Gold Member
Serum Indices Control
Acusera Serum Indices Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image Credit: Adobe Stock

AI in Cancer Diagnosis and Molecular Testing Takes Center Stage at AMP 2026

Artificial intelligence (AI) is increasingly being integrated into molecular diagnostics, offering new approaches to interpreting complex genetic information, classifying cancers, and optimizing laboratory testing.... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Graphical Abstract (Matthew A Butzler, Jennifer L Reed, Alaina M Olson, et al. Development of a Rapid Automated Point-of-Care Test for Mycobacterium tuberculosis Detection from Tongue Swabs and Sputum Specimens on the DASH® Rapid PCR System, Open Forum Infectious Diseases, 2026; https://doi.org/10.1093/ofid/ofag706)

Rapid Point-of-Care Test Detects Tuberculosis from Tongue Swab and Sputum

Tuberculosis remains a major infectious disease challenge, particularly in regions with limited access to diagnostic testing and treatment. Diagnosis can be time-consuming, and collecting sputum samples... Read more

Pathology

view channel
Image Credit: Adobe Stock

New Training Approach Helps AI Distinguish Neighboring Cells in Tissue

Artificial intelligence (AI) can assist with identifying cells in digital pathology images, but densely packed tissue remains difficult to analyze. Neighboring cells may be merged, counted twice, or missed,... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.